Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis
Authors
Keywords
Adverse effects, Aromatase inhibitors, Breast cancer, Clinical outcomes, <em class=EmphasisTypeItalic >CYP19A1</em>, Meta-analysis, Pharmacogenetics, Systematic review
Journal
BMC Medicine
Volume 13, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-06-11
DOI
10.1186/s12916-015-0373-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial
- (2014) Duveken B. Y. Fontein et al. BREAST CANCER RESEARCH AND TREATMENT
- Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER (+) breast cancer
- (2013) Nicola Napoli et al. BONE
- Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women
- (2013) Adnan Aydiner BREAST
- Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer
- (2013) N. Lynn Henry et al. BREAST CANCER RESEARCH AND TREATMENT
- A Polymorphism at the 3'-UTR Region of the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor, Anastrozole, in Metastatic Breast Carcinoma
- (2013) Lei Liu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Endometrial Intracrinology—Generation of an Estrogen-dominated Microenvironment in the Secretory Phase of Women
- (2013) D. A. Gibson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole
- (2012) G. Lunardi et al. BREAST CANCER RESEARCH AND TREATMENT
- Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients
- (2012) Roberta Ferraldeschi et al. BREAST CANCER RESEARCH AND TREATMENT
- Pharmacogenetics of aromatase inhibitors
- (2012) Kristen D Hadfield et al. PHARMACOGENOMICS
- The 2,2′,4,4′-tetrabromodiphenyl ether hydroxylated metabolites 5-OH-BDE-47 and 6-OH-BDE-47 stimulate estradiol secretion in the ovary by activating aromatase expression
- (2012) Anna Karpeta et al. TOXICOLOGY
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer
- (2011) In Hae Park et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Aromatase, aromatase inhibitors, and breast cancer
- (2011) Saranya Chumsri et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis
- (2011) Eitan Amir et al. JNCI-Journal of the National Cancer Institute
- A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole
- (2010) Zaida Garcia-Casado et al. BMC CANCER
- Association between CYP19 polymorphisms and breast cancer risk: results from 10,592 cases and 11,720 controls
- (2010) Xiangyu Ma et al. BREAST CANCER RESEARCH AND TREATMENT
- Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors
- (2010) L. Wang et al. CANCER RESEARCH
- A review of mechanistic studies on aromatase (CYP19) and 17α-hydroxylase-17,20-lyase (CYP17)
- (2010) Muhammad Akhtar et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
- (2009) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- Association of genetic polymorphisms of ER-α and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women
- (2008) Lina Zhang et al. BREAST CANCER RESEARCH AND TREATMENT
- A Single-Nucleotide Polymorphism in the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor Letrozole in Advanced Breast Carcinoma
- (2008) R. Colomer et al. CLINICAL CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now